KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Cash from Investing Activities: 2012-2024

Historic Cash from Investing Activities for Travere Therapeutics (TVTX) over the last 13 years, with Dec 2024 value amounting to $99.3 million.

  • Travere Therapeutics' Cash from Investing Activities rose 87.73% to $86.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.4 million, marking a year-over-year decrease of 67.53%. This contributed to the annual value of $99.3 million for FY2024, which is 165.51% up from last year.
  • As of FY2024, Travere Therapeutics' Cash from Investing Activities stood at $99.3 million, which was up 165.51% from -$151.6 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Cash from Investing Activities registered a high of $99.3 million during FY2024, and its lowest value of -$151.6 million during FY2023.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$32.6 million (2022), whereas its average is -$28.3 million.
  • Per our database at Business Quant, Travere Therapeutics' Cash from Investing Activities crashed by 408.75% in 2020 and then soared by 165.51% in 2024.
  • Travere Therapeutics' Cash from Investing Activities (Yearly) stood at -$61.3 million in 2020, then plummeted by 124.41% to -$137.6 million in 2021, then spiked by 76.35% to -$32.6 million in 2022, then plummeted by 365.78% to -$151.6 million in 2023, then surged by 165.51% to $99.3 million in 2024.